AlphaMadera's AlphaVal page computes OptimizeRx Corporation's fair value using a multi-method blend (DCF, comparable-multiples, and Graham-style intrinsic value), then compares it to the current market price to flag OPRX as undervalued, fairly valued, or overvalued.

What is OptimizeRx Corporation's fair value?

Fair value for OPRX is a model output combining discounted cash flow projections, peer-group multiples, and a Graham number floor. The live AlphaVal page shows the blended fair value alongside each method's individual estimate.

How does AlphaMadera value OPRX?

AlphaVal uses three primary techniques: a five-year discounted-cash-flow projection with terminal multiple, peer-group multiple analysis (P/E, EV/EBITDA, P/S), and Graham's defensive-investor intrinsic-value formula. Inputs come from OPRX's most recent reported fundamentals.

OPRX - OptimizeRx Corporation

Price: -- -- | CONSENSUS: Buy DETAILS | PRICE TARGET: $10.50 DETAILS

AlphaVal

Deterministic, archetype-aware fair value

AlphaVal Unavailable

AlphaVal: OPRX intrinsic value ($54) is 11x the stock price ($4.94). Likely stale financials (post-split price with pre-split EPS), ADR currency mismatch, or bad data.